Pacira's EXPAREL Linked to Reduced Opioid Use, Lower Costs in Shoulder Surgery Study
PCRX sits 31% above its 52-week low of $18.8.
Summary
Pacira BioSciences reported positive real-world study results for its key pain management product, EXPAREL. The study, presented at ISPOR 2026, found that EXPAREL use was associated with significantly reduced opioid consumption and lower healthcare costs in Medicare Advantage patients undergoing total shoulder arthroplasty. This data strengthens EXPAREL's value proposition for broader adoption and improved reimbursement, particularly as non-opioid pain management gains national focus. This positive product development provides a business-focused update amidst the company's ongoing proxy contest.
At the time of this announcement, PCRX was trading at $24.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $958.2M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.